Literature DB >> 28716896

Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers.

Vasudha Murlidhar1,2,3, Rishindra M Reddy4, Shamileh Fouladdel2,3,5, Lili Zhao6, Martin K Ishikawa7, Svetlana Grabauskiene4, Zhuo Zhang1,2,3, Jules Lin4, Andrew C Chang4, Philip Carrott4, William R Lynch4, Mark B Orringer4, Chandan Kumar-Sinha7, Nallasivam Palanisamy8, David G Beer4, Max S Wicha2,3,5, Nithya Ramnath5, Ebrahim Azizi2,3,5, Sunitha Nagrath9,2,3.   

Abstract

Early detection of metastasis can be aided by circulating tumor cells (CTC), which also show potential to predict early relapse. Because of the limited CTC numbers in peripheral blood in early stages, we investigated CTCs in pulmonary vein blood accessed during surgical resection of tumors. Pulmonary vein (PV) and peripheral vein (Pe) blood specimens from patients with lung cancer were drawn during the perioperative period and assessed for CTC burden using a microfluidic device. From 108 blood samples analyzed from 36 patients, PV had significantly higher number of CTCs compared with preoperative Pe (P < 0.0001) and intraoperative Pe (P < 0.001) blood. CTC clusters with large number of CTCs were observed in 50% of patients, with PV often revealing larger clusters. Long-term surveillance indicated that presence of clusters in preoperative Pe blood predicted a trend toward poor prognosis. Gene expression analysis by RT-qPCR revealed enrichment of p53 signaling and extracellular matrix involvement in PV and Pe samples. Ki67 expression was detected in 62.5% of PV samples and 59.2% of Pe samples, with the majority (72.7%) of patients positive for Ki67 expression in PV having single CTCs as opposed to clusters. Gene ontology analysis revealed enrichment of cell migration and immune-related pathways in CTC clusters, suggesting survival advantage of clusters in circulation. Clusters display characteristics of therapeutic resistance, indicating the aggressive nature of these cells. Thus, CTCs isolated from early stages of lung cancer are predictive of poor prognosis and can be interrogated to determine biomarkers predictive of recurrence. Cancer Res; 77(18); 5194-206. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28716896      PMCID: PMC5600850          DOI: 10.1158/0008-5472.CAN-16-2072

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  55 in total

1.  Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology.

Authors:  Marco Wendel; Lyudmila Bazhenova; Rogier Boshuizen; Anand Kolatkar; Meghana Honnatti; Edward H Cho; Dena Marrinucci; Ajay Sandhu; Anthony Perricone; Patricia Thistlethwaite; Kelly Bethel; Jorge Nieva; Michel van den Heuvel; Peter Kuhn
Journal:  Phys Biol       Date:  2012-02-03       Impact factor: 2.583

2.  Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer.

Authors:  Massimiliano Bissolati; Maria Teresa Sandri; Giovanni Burtulo; Laura Zorzino; Gianpaolo Balzano; Marco Braga
Journal:  Tumour Biol       Date:  2014-10-16

3.  Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.

Authors:  Shannon L Stott; Richard J Lee; Sunitha Nagrath; Min Yu; David T Miyamoto; Lindsey Ulkus; Elizabeth J Inserra; Matthew Ulman; Simeon Springer; Zev Nakamura; Alessandra L Moore; Dina I Tsukrov; Maria E Kempner; Douglas M Dahl; Chin-Lee Wu; A John Iafrate; Matthew R Smith; Ronald G Tompkins; Lecia V Sequist; Mehmet Toner; Daniel A Haber; Shyamala Maheswaran
Journal:  Sci Transl Med       Date:  2010-03-31       Impact factor: 17.956

Review 4.  Overcoming treatment resistance in cancer: Current understanding and tactics.

Authors:  Guang Wu; George Wilson; Jacob George; Christopher Liddle; Lionel Hebbard; Liang Qiao
Journal:  Cancer Lett       Date:  2016-04-14       Impact factor: 8.679

5.  Novel approach for detection of isolated tumor cells in pulmonary vein using negative selection method: morphological classification and clinical implications.

Authors:  Soichiro Funaki; Noriyoshi Sawabata; Tomoyuki Nakagiri; Yasushi Shintani; Masayoshi Inoue; Yoshiki Kadota; Masato Minami; Meinoshin Okumura
Journal:  Eur J Cardiothorac Surg       Date:  2011-01-07       Impact factor: 4.191

Review 6.  Interleukin-6 signaling pathway in targeted therapy for cancer.

Authors:  Yuqi Guo; Feng Xu; TianJian Lu; Zhenfeng Duan; Zhan Zhang
Journal:  Cancer Treat Rev       Date:  2012-05-29       Impact factor: 12.111

7.  Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.

Authors:  Matthew G Krebs; Jian-Mei Hou; Robert Sloane; Lee Lancashire; Lynsey Priest; Daisuke Nonaka; Tim H Ward; Alison Backen; Glen Clack; Andrew Hughes; Malcolm Ranson; Fiona H Blackhall; Caroline Dive
Journal:  J Thorac Oncol       Date:  2012-02       Impact factor: 15.609

Review 8.  EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.

Authors:  Tsukasa Shibue; Robert A Weinberg
Journal:  Nat Rev Clin Oncol       Date:  2017-04-11       Impact factor: 66.675

9.  A radial flow microfluidic device for ultra-high-throughput affinity-based isolation of circulating tumor cells.

Authors:  Vasudha Murlidhar; Mina Zeinali; Svetlana Grabauskiene; Mostafa Ghannad-Rezaie; Max S Wicha; Diane M Simeone; Nithya Ramnath; Rishindra M Reddy; Sunitha Nagrath
Journal:  Small       Date:  2014-07-29       Impact factor: 13.281

10.  Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.

Authors:  Sabine Kasimir-Bauer; Ann-Kathrin Bittner; Lisa König; Katharina Reiter; Thomas Keller; Rainer Kimmig; Oliver Hoffmann
Journal:  Breast Cancer Res       Date:  2016-02-12       Impact factor: 6.466

View more
  51 in total

1.  PD-L1 Expression on Lung Cancer Stem Cells in Metastatic Lymph Nodes Aspirates.

Authors:  Agata Raniszewska; Małgorzata Polubiec-Kownacka; Elzbieta Rutkowska; Joanna Domagala-Kulawik
Journal:  Stem Cell Rev Rep       Date:  2019-04       Impact factor: 5.739

2.  In Vivo Flow Cytometry.

Authors:  Xi Zhu; Qi Liu; Yuting Fu; Fuli Zhang; Zhengqin Gu; Bobo Gu; Xunbin Wei
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Cell adhesion in cancer: Beyond the migration of single cells.

Authors:  Michalina Janiszewska; Marina Candido Primi; Tina Izard
Journal:  J Biol Chem       Date:  2020-01-14       Impact factor: 5.157

Review 4.  An emerging tumor invasion mechanism about the collective cell migration.

Authors:  Yang Yang; Hongmei Zheng; Yuting Zhan; Songqing Fan
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

5.  Preface to the Special Topic: Microfluidics, Circulating Biomarkers and Cancer.

Authors:  Siva A Vanapalli; Soojung Clair Hur
Journal:  Biomicrofluidics       Date:  2022-08-16       Impact factor: 3.258

6.  Wedge Resection of Tumor Before Lobectomy for Lung Cancer Could Be a No-touch Isolation Technique.

Authors:  Motoaki Yasukawa; Noriyoshi Sawabata; Takeshi Kawaguchi; Shigeki Taniguchi
Journal:  In Vivo       Date:  2020 Mar-Apr       Impact factor: 2.155

7.  Microfluidic device for high-throughput affinity-based isolation of extracellular vesicles.

Authors:  Ting-Wen Lo; Ziwen Zhu; Emma Purcell; Daniel Watza; Joyful Wang; Yoon-Tae Kang; Shruti Jolly; Deepak Nagrath; Sunitha Nagrath
Journal:  Lab Chip       Date:  2020-05-19       Impact factor: 6.799

Review 8.  Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal.

Authors:  Alexios-Fotios A Mentis; Petros D Grivas; Efthimios Dardiotis; Nicholas A Romas; Athanasios G Papavassiliou
Journal:  Cell Mol Life Sci       Date:  2020-04-24       Impact factor: 9.261

Review 9.  Prognostic and therapeutic significance of circulating tumor cells in patients with lung cancer.

Authors:  Meysam Yousefi; Parisa Ghaffari; Rahim Nosrati; Sadegh Dehghani; Arash Salmaninejad; Yousef Jafari Abarghan; Seyed H Ghaffari
Journal:  Cell Oncol (Dordr)       Date:  2019-12-11       Impact factor: 6.730

Review 10.  Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical Practice.

Authors:  Chiara Agnoletto; Chiara Caruso; Cecilia Garofalo
Journal:  Cancers (Basel)       Date:  2021-05-02       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.